Autonomic Testing for Diabetic Neuropathy: A Clinical Guide

Why Autonomic Testing Matters for Diabetic Patients

Diabetic Autonomic Neuropathy (DAN) affects up to 50% of patients with diabetes and is a strong predictor of mortality. Yet it often goes undetected until late-stage symptoms appear — silent MI, orthostatic hypotension, or sudden cardiac death.

The American Diabetes Association (ADA) recommends autonomic nervous system testing as a standard of care for patients with Type 1 and Type 2 diabetes.

What DAN Looks Like Clinically

• Cardiac: resting tachycardia, orthostatic hypotension, exercise intolerance
• Gastrointestinal: gastroparesis, constipation, diarrhea
• Sudomotor: dry skin, anhidrosis, heat intolerance
• Vascular: abnormal blood flow regulation, edema

How VitalScan ANS+ Detects DAN Early

The VitalScan ANS+ System performs a comprehensive autonomic assessment in approximately 15 minutes, measuring:

1. Heart Rate Variability (HRV) at rest and during deep breathing
2. Valsalva ratio to assess parasympathetic function
3. Orthostatic blood pressure response to detect orthostatic hypotension
4. Sudomotor function via SudoCheck to assess small nerve fiber integrity

Implementing ANS Testing in Your Practice

The test is administered by your existing clinical staff — no specialized technician required. The automated interpretive report is ready before the patient leaves the office, enabling same-visit counseling and treatment planning.

Billing: Covered under CPT codes 95921–95924. Most major insurers reimburse ANS testing for diabetic patients with documented neuropathy risk factors.

Key Takeaway

Early detection of DAN enables timely intervention — glycemic optimization, lifestyle changes, and medication adjustments — that can slow progression and reduce mortality risk. With the ADA's recommendation and straightforward CPT billing, ANS testing is both a clinical and financial win for your practice.